Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T<sub>reg</sub> cells

Nature, Published online: 28 February 2024; doi:10.1038/s41586-024-07121-9A high baseline of intratumoural macrophages and regulatory T cells is associated with better outcomes in patients with non-small cell lung cancer treated with atezolizumab plus tiragolumab, but not with atezolizumab alone.

  Nature & & science   Feb 28, 2024   0   38  Add to Reading List
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T<sub>reg</sub> cells

Nature, Published online: 28 February 2024; doi:10.1038/s41586-024-07121-9

A high baseline of intratumoural macrophages and regulatory T cells is associated with better outcomes in patients with non-small cell lung cancer treated with atezolizumab plus tiragolumab, but not with atezolizumab alone.
Visit site   

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow